Phase 3 Recruiting Network
This trial has two cohorts of patients with human epidermal growth factor receptor (HER)-2-positive breast cancer that has spread to other places in the body. All patients must be receiving trastuzumab-based treatment. Both cohorts are bei…
Sponsor: SWOG Cancer Research Network
NCT ID: NCT03418961
Sites in Texas: - Saint Joseph Regional Cancer Center — Bryan, Texas
- UT Southwestern/Simmons Cancer Center-Dallas — Dallas, Texas
- UT Southwestern/Simmons Cancer Center-Fort Worth — Fort Worth, Texas
- UMC Cancer Center / UMC Health System — Lubbock, Texas
- UT Southwestern Clinical Center at Richardson/Plano — Richardson, Texas
Phase 3 Recruiting Network
This phase III trial tests two hypotheses in patients with low-risk and average-risk medulloblastoma. Medulloblastoma is a type of cancer that occurs in the back of the brain. The term, risk, refers to the chance of the cancer coming back …
Sponsor: Children's Oncology Group
NCT ID: NCT05382338
Sites in Texas: - Dell Children's Medical Center of Central Texas — Austin, Texas
- Driscoll Children's Hospital — Corpus Christi, Texas
- Medical City Dallas Hospital — Dallas, Texas
- UT Southwestern/Simmons Cancer Center-Dallas — Dallas, Texas
- El Paso Children's Hospital — El Paso, Texas
Phase 3 Recruiting Industry
This is a randomized, double-blind, placebo-controlled, parallel-group, international, Phase 3 study in patients with newly diagnosed H3 K27M-mutant diffuse glioma to assess whether treatment with dordaviprone (ONC201) following frontline …
Sponsor: Jazz Pharmaceuticals
NCT ID: NCT05580562
Sites in Texas: - Dell Children's Medical Center of Central Texas — Austin, Texas
- Neuro-Oncology Associates — Dallas, Texas
- University of Texas Southwestern Medical Center — Dallas, Texas
- University of Texas MD Anderson Cancer Center — Houston, Texas
- UT Health Houston Neurosciences - Texas Medical Center — Houston, Texas
Phase 3 Recruiting Industry
This is a 3-part study. The purpose of Part 1 of the study is to evaluate the efficacy, safety, and pharmacokinetic (PK) characteristics of safusidenib in participants with recurrent/progressive IDH1-mutant World Health Organization (WHO) …
Sponsor: Nuvation Bio Inc.
NCT ID: NCT05303519
Sites in Texas: - University of Texas Southwestern Medical Center — Dallas, Texas
- MD Anderson Cancer Center — Houston, Texas
- University of Texas Health Mays Cancer Center — San Antonio, Texas
Phase 2, Phase 3 Recruiting Academic/Other
Glioblastoma (GBM) adaptive, global, innovative learning environment (GBM AGILE) is an international, seamless Phase II/III response adaptive randomization platform trial designed to evaluate multiple therapies in newly diagnosed (ND) and …
Sponsor: Global Coalition for Adaptive Research
NCT ID: NCT03970447
Sites in Texas: - Texas Oncology - Austin — Austin, Texas
- University of Texas Southwestern Medical Center — Dallas, Texas
- University of Texas - MD Anderson Cancer Center — Houston, Texas
Phase 3 Recruiting Industry
This is a multicenter, two-arm, randomized, double-blind, placebo-controlled study of Optune® (Tumor Treating Fields at 200 kHz) together with maintenance Temozolomide (TMZ) chemotherapy agent and pembrolizumab compared to Optune® together…
Sponsor: NovoCure GmbH
NCT ID: NCT06556563
Sites in Texas: - The University of Texas — Houston, Texas
- University of Texas, MD Anderson Cancer Center — Houston, Texas
Phase 3 Recruiting Industry
The brain is protected from any toxic or inflammatory molecule by the blood-brain barrier (BBB). This physical barrier is located at the level of the blood vessel walls. Because of these barrier properties, the blood vessels are also imper…
Sponsor: CarThera
NCT ID: NCT05902169
Sites in Texas: - University of Texas Southwestern Medical Center — Dallas, Texas
- University of Texas Houston Health Science Center — Houston, Texas
Phase 1, Phase 2 Recruiting Network
This phase I/II trial evaluates the best dose, side effects and possible benefit of CBL0137 in treating patients with solid tumors, including central nervous system (CNS) tumors or lymphoma that has come back (relapsed) or does not respond…
Sponsor: Children's Oncology Group
NCT ID: NCT04870944
Sites in Texas: - UT Southwestern/Simmons Cancer Center-Dallas — Dallas, Texas
- Cook Children's Medical Center — Fort Worth, Texas
- Baylor College of Medicine/Dan L Duncan Comprehensive Cancer Center — Houston, Texas
Phase 1, Phase 2 Recruiting Academic/Other
BDTX-4933-101 is a first-in-human, open-label, Phase 1/2 dose escalation, dose optimization and expansion study designed to evaluate the safety and tolerability of S241656 as monotherapy and in combination with other anti-cancer therapies …
Sponsor: Institut de Recherches Internationales Servier
NCT ID: NCT05786924
Sites in Texas: - MD Anderson Cancer Center — Houston, Texas
- START San Antonio — San Antonio, Texas
Phase 1, Phase 2 Recruiting Industry
Phase 1 will evaluate the safety and tolerability at different dose levels of repotrectinib in pediatric and young adult subjects with advanced or metastatic malignancies harboring anaplastic lymphoma kinase (ALK), receptor tyrosine kinase…
Sponsor: Turning Point Therapeutics, Inc.
NCT ID: NCT04094610
Sites in Texas: - The University of Texas Southwestern Medical Center - Harold C Simmons Comprehensive Cancer Center — Dallas, Texas
- Baylor College of Medicine — Houston, Texas
- Local Institution - 2104 — Houston, Texas
Phase 2 Recruiting Industry
The objective of the study is to evaluate efficacy and safety of zanzalintinib in participants with recurrent or progressive meningioma refractory to standard therapies.
Sponsor: Exelixis
NCT ID: NCT07428616
Sites in Texas: - UT MD Anderson Cancer Center — Houston, Texas
- UT Health San Antonio Mays Cancer Center — San Antonio, Texas
Phase 1, Phase 2 Recruiting Industry
This is a first in human study of TNG456 alone and in combination with abemaciclib in patients with advanced or metastatic solid tumors known to have an MTAP loss. The first part of the study is an open-label, dose escalation and the secon…
Sponsor: Tango Therapeutics, Inc.
NCT ID: NCT06810544
Sites in Texas: - MD Anderson Cancer Center — Houston, Texas
Phase 2 Recruiting Industry
This is a Phase 2, multi center, open-label study to evaluate the safety and efficacy of Type II RAF (tovorafenib) in pediatric participants with low-grade glioma or advanced solid tumors. Qualifying genomic alterations will be identified …
Sponsor: Day One Biopharmaceuticals, Inc.
NCT ID: NCT04775485
Sites in Texas: - Texas Children's Hospital — Houston, Texas
Phase 2 Recruiting Academic/Other
This study will address the question of whether targeting CMV antigens with PEP-CMV can serve as a novel immunotherapeutic approach in pediatric patients with newly-diagnosed high-grade glioma (HGG) or diffuse intrinsic pontine glioma (DIP…
Sponsor: Nationwide Children's Hospital
NCT ID: NCT05096481
Sites in Texas: - Texas Children's Hospital — Houston, Texas
Phase 2 Recruiting Academic/Other
This research study is studying several investigational drugs as a possible treatment for Glioblastoma (GBM). The drugs involved in this study are : * Abemaciclib (arm is currently closed to accrual) * Temozolomide (temodar) * Neratinib (a…
Sponsor: David Reardon, MD
NCT ID: NCT02977780
Sites in Texas: - UT MD Anderson Cancer Center — Houston, Texas
Phase 2 Recruiting Academic/Other
The goal of this study is to determine the efficacy of the 1) ribociclib and everolimus to treat pediatric and young adult patients newly diagnosed with a high-grade glioma (HGG), including DIPG, that have genetic changes in pathways (cell…
Sponsor: Nationwide Children's Hospital
NCT ID: NCT05843253
Sites in Texas: - Texas Children's Hospital — Houston, Texas
Phase 1, Phase 2 Recruiting Industry
This multi-site, Phase 1/2 clinical trial is an open-label study to identify the safety, pharmacokinetics, and efficacy of a repeated dose regimen of NEO212 alone for the treatment of patients with radiographically-confirmed progression of…
Sponsor: Neonc Technologies, Inc.
NCT ID: NCT06047379
Sites in Texas: - Baylor, Scott and White Research Institute — Dallas, Texas
Phase 1, Phase 2 Recruiting Industry
The primary purpose of the Phase 1 (Dose Escalation) of this study is to identify the dose-limiting toxicities (DLTs) of Debio 0123 combined with temozolomide (TMZ) (Arm A) and with TMZ and radiotherapy (RT) (Arms B and C) and to character…
Sponsor: Debiopharm International SA
NCT ID: NCT05765812
Sites in Texas: - Baylor Scott & White Research Institute — Dallas, Texas
- The University of Texas MD Anderson Cancer Center — Houston, Texas
- South Texas Accelerated Research Therapeutics (START) — San Antonio, Texas
Phase 1, Phase 2 Recruiting Industry
This study will evaluate the safety, tolerability, and preliminary efficacy of EIK1004 (IMP1707) in participants with recurrent advanced/metastatic breast cancer, ovarian cancer, metastatic castrate resistant prostate cancer (mCRPC) and pa…
Sponsor: Eikon Therapeutics
NCT ID: NCT06907043
Sites in Texas: - MD Anderson — Houston, Texas
- NEXT Oncology — San Antonio, Texas
Phase 2 Recruiting Academic/Other
This is an open-label single arm study. All patients will receive the study drug. The aim of the study is to compare overall survival (OS) of patients with recurrent brain tumor, known as Glioblastoma (GBM) having high levels of a protein,…
Sponsor: The University of Texas Health Science Center at San Antonio
NCT ID: NCT04559230
Sites in Texas: - Texas Oncology Austin — Austin, Texas
- University of Texas Health Science Center San Antonio at the Cancer Therapy and Research Center — San Antonio, Texas
Phase 1, Phase 2 Recruiting Academic/Other
The goal of Phase 1 of this clinical research study is to find the highest tolerable dose and the recommended Phase 2 dose of ivonescimab that can be given to patients who have recurrent glioblastoma. The goal of Phase 2 of this clinical r…
Sponsor: M.D. Anderson Cancer Center
NCT ID: NCT06672575
Sites in Texas: - The University of Texas M. D. Anderson Cancer Center — Houston, Texas
- The University of Texas MD Anderson Cancer Center — Houston, Texas
Phase 2 Recruiting Academic/Other
This phase II trial studies how well temozolomide and radiation therapy work in treating patients with IDH wildtype historically lower grade gliomas or non-histological molecular glioblastomas. Radiation therapy uses high-energy x-rays to …
Sponsor: M.D. Anderson Cancer Center
NCT ID: NCT04623931
Sites in Texas: - M D Anderson Cancer Center — Houston, Texas
Phase 2 Recruiting Academic/Other
A Phase II Study of Nivolumab with Ipilimumab and Cabozantinib in Patients with Untreated Renal Cell Carcinoma Brain Metastases
Sponsor: M.D. Anderson Cancer Center
NCT ID: NCT05048212
Sites in Texas: - M D Anderson Cancer Center — Houston, Texas
Phase 2 Recruiting Academic/Other
To learn if the study drugs, tucatinib and adotrastuzumab emtansine (T-DM1), can help to control solid tumors that have spread to the brain.
Sponsor: M.D. Anderson Cancer Center
NCT ID: NCT05673928
Sites in Texas: - M D Anderson Cancer Center — Houston, Texas
Phase 2 Recruiting Academic/Other
The goal of this clinical research study is to learn about the safety and effects of G207 combined with radiation therapy in patients with recurrent or progressive high-grade glioma (HGG).
Sponsor: M.D. Anderson Cancer Center
NCT ID: NCT07649070
Sites in Texas: - UT MD Anderson — Houston, Texas